In a phase Ib trial, ADU-S100 combined with spartalizumab (anti-PD-1) led to partial responses only in PD-1–relapsed/refractory melanoma and PD-1-naïve triple negative breast cancer patients (37). The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.